A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio in Germany comprises products in HematoOncology. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
Anagrelide AOP® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.
Canemes® prevents nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.